Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study (Q33880042)

29 July 2017

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study (English)

1 reference

multicenter clinical trial

29 July 2017

0 references

1 reference

Scott Antonia

1

1 reference

29 July 2017

Sarah B Goldberg

2

1 reference

29 July 2017

Ani Balmanoukian

3

1 reference

29 July 2017

Jamie E Chaft

4

1 reference

29 July 2017

Rachel E Sanborn

5

1 reference

29 July 2017

Ashok Gupta

6

1 reference

29 July 2017

Rajesh Narwal

7

1 reference

29 July 2017

Keith Steele

8

1 reference

29 July 2017

Yu Gu

9

1 reference

29 July 2017

Joyson J Karakunnel

10

1 reference

29 July 2017

Naiyer A Rizvi

11

1 reference

29 July 2017

5 February 2016

1 reference

Lancet Oncology Commission

29 July 2017

1 reference

29 July 2017

17

1 reference

29 July 2017

299-308

1 reference

29 July 2017

3

1 reference

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Immuno-oncology combinations: a review of clinical experience and future prospects

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Innate and adaptive immune cells in the tumor microenvironment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Nivolumab plus ipilimumab in advanced melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Tremelimumab: a review of development to date in solid tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

A parallel phase I/II clinical trial design for combination therapies.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500167

29 October 2018

PD-1/PD-L1 inhibitors.

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900544-6

inferred from DOI database lookup

7 January 2021

based on heuristic

B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900544-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S1470-2045(15)00544-6

1 reference

29 July 2017

1 reference

29 July 2017

1 reference